Pfizer announces today acquisition of Bamboo Therapeutic, Inc. as a part of a growing commitment to gene therapy and rare disease, including FA. Bamboo’s portfolio includes potential best-in-class rAAV-based gene therapies in two priority areas: neuromuscular, with a pre-clinical asset for Duchenne Muscular Dystrophy (DMD); and central nervous system, with pre-clinical assets for Friedreich’s Ataxia and Canavan disease, and a Phase I asset for Giant Axonal Neuropathy.
For more information on Pfizer's interest in developing therapies for FA and rare disease visit:
Video with Pfizer Scientist Joe Nabhan, talking about his work on drug discovery for FA:

Read the Pfizer Press Release HERE